Aggressive B-Zell-Lymphome

GOAL II

• Status: aktiv, Eudract Nr. 2019-002373-59
• A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Mor208 for patients with relapsed/refractory aggressive lymphoma
• Ansprechpartner:
  Prof. Dr. Gerald Illerhaus
  Telefon: 0711 278-30401
  E-Mail: g.illerhaus@klinikum-stuttgart.de
• Studienzentrale
  Telefon: 0711 278-30410, -30411, -30414
  E-Mail: scc-studienzentrale@klinikum-stuttgart.de